SEC Form 4 · accession 0001209191-15-053867
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Norman C Selby
Director
Period of report
Jun 15, 2015
Accepted (ET)
Jun 16, 2015 · 4:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $11.06 | Jun 15, 2015 | A | 15,000 | A | — | Jun 15, 2015 | Common Stock | 15,000 | 15,000 | D |
| Stock Option (right to buy)F2 | $11.06 | Jun 15, 2015 | A | 10,000 | A | — | Jun 15, 2015 | Common Stock | 10,000 | 10,000 | D |
| Stock Option (right to buy)F3 | $11.06 | Jun 15, 2015 | A | 2,000 | A | — | Jun 15, 2015 | Common Stock | 2,000 | 2,000 | D |
Explanation of responses
- F1The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
- F2The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Lead Outside Director of the issuer's Board of Directors.
- F3The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Compensation Committee of the issuer's Board of Directors.